wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q57039929-51F9BFFE-38B0-4995-989C-9E5EBDD54189
Q57039929-51F9BFFE-38B0-4995-989C-9E5EBDD54189
BestRank
Statement
http://www.wikidata.org/entity/statement/Q57039929-51F9BFFE-38B0-4995-989C-9E5EBDD54189
Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis
P2860
Q57039929-51F9BFFE-38B0-4995-989C-9E5EBDD54189
BestRank
Statement
http://www.wikidata.org/entity/statement/Q57039929-51F9BFFE-38B0-4995-989C-9E5EBDD54189
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5b8355ce9c1bc00a2778b521ca6e53bcf9d8aa2c
P2860
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.